http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_30ded0c82021d1ffebe0b1c4ad802c4f
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Rennert |
| name | Gad Rennert |
| given-name | Gad |
| organization-name | 147Clalit National Cancer Control Center, Haifa, Israel. Lea Hagoel, Nili Stein, and Gad Rennert are with the Department of Community Medicine and Epidemiology, Carmel Medical Center and Faculty of Medicine, Technion, Haifa, Israel. Efrat Neter is with the Department of Behavioral Sciences, Ruppin Academic Center, Emeq Hefer, Israel. Clalit National Cancer Control Center at Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel. 3Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel.; 4Clalit Health Services National Cancer Control Center, Haifa, Israel.; 5Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Department of Community Medicine & Epidemiology, Lady Davis Carmel Medical Center, Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; Steve and Cindy Rasmussen Institute for Genomic Medicine, Lady Davis Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel From the Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology; and Clalit Health Services National Cancer Control Center, Haifa, Israel. 4Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel.; 5Clalit Health Services National Cancer Control Center, Haifa, Israel.; 6Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Technion Carmel Medical Center, Haifa, Israel Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center , Haifa, Israel Authors' Affiliations: 1Unit of Biomarkers and Susceptibility and 2Medical Oncology Service, Catalan Institute of Oncology (ICO), IDIBELL, and CIBERESP, Departments of 3Digestive Surgery and 4Pathology, University Hospital Bellvitge, L'Hospitalet de Llobregat; 5Department of Medical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain; 6Clalit Health Services National Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; 7Rambam Medical Center; 8Bnai Zion Medical Center; 9Carmel Medical Center, Haifa; 10Western Galilee Medical Center, Nahariya; and 11Haemek Medical Center, Afula, Israel; and Departments of 12Environmental Health Sciences, 13Pathology, and 14Internal Medicine, Epidemiology, Human Genetics, University of Michigan, Ann Arbor, Michigan Department of Community Medicine and Epidemiology, Carmel Medical Center, B. Rappaport Faculty of Medicine, Technion, Haifa, Israel Department of Community Medicine and Epidemiology Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Israel Institute of Technology and Clalit Health Services National Cancer Control Center Haifa Israel 12Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B Rappaport Faculty of Medicine, Haifa, Israel. Department of Community Medicine and Epidemiology Lady Davis Carmel Medical Center Haifa Israel; Faculty of Medicine Technion‐Israel Institute of Technology Haifa Israel 1Department of Community Medicine and Epidemiology, Clalit Health Services National Cancer Control Center, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Departments of 10Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Department of Community Medicine and Epidemiology, Carmel Medical Center and Technion Faculty of Medicine, Haifa 34362, Israel. 4Department of Community Medicine and Epidemiology, Carmel Medical Center and Technion Faculty of Medicine; and; 5CHS National Cancer Control Center, Haifa, Israel Authors' Affiliations: Departments of 1Internal Medicine, 2Radiation Oncology, and 3Human Genetics, University of Michigan Medical School; Departments of 4Epidemiology and 5Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan; 6Biostatistics and Bioinformatics Unit, IDIBELL-Catalan Institute of Oncology and University of Barcelona, Barcelona, Spain; 7Clalit Health Services, National Cancer Control Center; 8Department of Community Medicine and Epidemiology, Carmel Medical Center; and 9B. Rappaport Faculty of Medicine, Technion, Haifa, Israel; Authors' Affiliations: Departments of 1Internal Medicine, 2Radiation Oncology, and 3Human Genetics, University of Michigan Medical School; Departments of 4Epidemiology and 5Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan; 6Biostatistics and Bioinformatics Unit, IDIBELL-Catalan Institute of Oncology and University of Barcelona, Barcelona, Spain; 7Clalit Health Services, National Cancer Control Center; 8Department of Community Medicine and Epidemiology, Carmel Medical Center; and 9B. Rappaport Faculty of Medicine, Technion, Haifa, Israel; Authors' Affiliations: Departments of 1Internal Medicine, 2Radiation Oncology, and 3Human Genetics, University of Michigan Medical School; Departments of 4Epidemiology and 5Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan; 6Biostatistics and Bioinformatics Unit, IDIBELL-Catalan Institute of Oncology and University of Barcelona, Barcelona, Spain; 7Clalit Health Services, National Cancer Control Center; 8Department of Community Medicine and Epidemiology, Carmel Medical Center; and 9B. Rappaport Faculty of Medicine, Technion, Haifa, Israel Clalit Health Services National Cancer Control Center at Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel. Technion Faculty of Medicine, Clalit National Cancer Control Center, Carmel Medical Center, Haifa, Israel Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel. From the Department of Community Medicine and Epidemiology (W.S., H.S.R., O.B.-G., N.G., G.R.), Statistical Unit (O.B.-G.), Pharmacoepidemiology and Pharmacogenetics Unit (N.G.), and Department of Neurology (E.A.), Lady Davis Carmel Medical Center; Ruth and Bruce Rappaport Faculty of Medicine (W.S., G.R., E.A.), Technion–Israel Institute of Technology, Haifa; and Department of Neurology (J.M.), Tel-Aviv Sourasky Medical Center, Israel. From Department of Community Medicine and Epidemiology, Carmel Medical Center; Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; Clalit Health Services National Cancer Control Center; Gyneco-oncology Unit, Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel; and Departments of Epidemiology, Internal Medicine, and Human Genetics, University of Michigan, Ann Arbor, MI. Department of Community Medicine and Epidemiology Lady Davis Carmel Medical Center Haifa Israel; Ruth and Bruce Rappaport Faculty of Medicine Technion–Israel Institute of Technology Haifa Israel Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology and Clalit National Cancer Control Center, Haifa, Israel Clalit Health Services National Cancer Control Center and Department of Community Medicine and Epidemiology at Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel 9Clalit Health Services, National Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion, Haifa, Israel Clalit National Cancer Control Center, at Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel Department of Community Medicine and Epidemiology (W.S., O.B., H.S.R., G.R.), Haifa 34362, Israel; Carmel Medical Center, Clalit Health Services, and Bruce Rappaport Faculty of Medicine (W.S., O.B., H.S.R., G.R.), Technion-Israel Institute of Technology, Haifa 34362, Israel; Department of Epidemiology and Disease Prevention (G.R.), Office of the Chief Physician, Clalit Health Services Headquarters, Tel Aviv 62098, Israel Department of Community Medicine and Epidemiology, Clalit Health Services, Haifa, Israel.; Ruth and Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa, Israel. Authors' Affiliations: 1Department of Biological Chemistry, Weizmann Institute of Science, Rehovot; 2Department of Community Medicine and Epidemiology, Carmel Medical Center, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, and Clalit Health Services National Cancer Control Center; 3Department of General Thoracic Surgery, Rambam Health Care Campus, Haifa; 4Department of Industrial Engineering and Management, Ben Gurion University of the Negev, Beer Sheva; and 5Biostatistics Unit, Gertner Institute for Epidemiology and Health Policy Research Sheba Medical Center, Tel Hashomer, Israel 8Department of Community Medicine and Epidemiology, Carmel Medical Center and Technion Faculty of Medicine; and; 9CHS National Cancer Control Center, Haifa, Israel Department of Community Medicine and Epidemiology Lady Davis Carmel Medical Center Haifa Israel; Ruth and Bruce Rappaport Faculty of Medicine Technion‐Israel Institute of Technology Haifa Israel; Clalit National Cancer Control Center Haifa Israel 4Clalit Health Services, National Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel; National Israeli Breast and Colorectal Cancer Detection Programs Ministry of Health and Israel Cancer Association, Department of Community Medicine and Epidemiology Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion, Israel; Department of Community Medicine and Epidemiology Faculty of Medicine Technion and Carmel Medical Center Haifa Israel Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center , Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology , Haifa, Israel; Clalit National Cancer Control Center , Haifa, Israel CHS National Cancer Control Center, Carmel Medical Center, Haifa, Israel. Authors' Affiliations: 1Department of Medicine, Weill Cornell School of Medicine, New York, New York; 2Department of Medicine, University of California, Irvine, Irvine, California; Departments of 3Internal Medicine, 4Epidemiology, 5Environmental Health Sciences, and 6Human Genetics, University of Michigan, Ann Arbor, Michigan; 7IDIBELL-Catalan Institute of Oncology (ICO) and University of Barcelona, Barcelona, Spain; 8Clalit Health Services National Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; and 9Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland Clalit National Cancer Control Center Carmel Medical Center and Technion Faculty of Medicine Haifa Israel Department of Community Medicine and Epidemiology Lady Davis Carmel Medical Center Haifa Israel; Ruth and Bruce Rappaport Faculty of Medicine Technion–Israel Institute of Technology Haifa Israel; Office of Chief Physician Clalit Health Services Tel Aviv Israel Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center Haifa Israel; Ruth and Bruce Rappaport Faculty of Medicine Technion–Israel Institute of Technology Haifa Israel Department of Community Medicine and Epidemiology Lady Davis Carmel Medical Center Clalit Health Services Haifa Israel; Ruth and Bruce Rappaport Faculty of Medicine Technion–Israel Institute of Technology Haifa Israel Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel. 5Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion, and Clalit Health Services National Cancer Control Center, Haifa, Israel Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; and; Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, 35254, Israel. Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Clalit Health Services, Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel Carmel Medical Center, Haifa, Israel. Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology; Clalit National Cancer Control Center, Haifa, Israel 4Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology and CHS National Cancer Control Center, Haifa, Israel Clalit National Cancer Control Center at Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel Clalit National Cancer Control Center, Carmel Medical Center, Haifa, Israel 5Department of Community Medicine and Epidemiology, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel and CHS National Cancer Control Center, Haifa, Israel 1Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology and Clalit National Cancer Control Center, Haifa, Israel. Lady Davis Carmel Medical Center, Haifa, Israel. Clalit Health Services National Israeli Cancer Control Center, Haifa, Israel; Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel; Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel From the Carmel Medical Center, Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, and Clalit Health Services National Cancer Control Center, Haifa, Israel; and University of Michigan, Ann Arbor, MI. Clalit National Cancer Control Center at Carmel Medical Center and Technion Faculty of Medicine , Haifa 3436212, Israel Clalit National Israeli Cancer Control Center, Haifa, Israel; Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion, Haifa, Israel. Katerina Shulman, Hillel Yaffe Medical Center, Hadera; Katerina Shulman, Ofra Barnett-Griness, Vered Friedman, Flavio Lejbkowicz, and Gad Rennert, Carmel Medical Center, and Technion, Haifa, Israel; Joel K. Greenson, University of Michigan, Ann Arbor, MI; and Stephen B. Gruber, University of Southern California, Los Angeles, CA. 57Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel.; 58Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.; 59Clalit National Cancer Control Center, Haifa, Israel. Department of Community Medicine and Epidemiology Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion‐Israel Institute of Technology and Clalit National Cancer Control Center Haifa Israel Pharmacoepidemiology and Pharmacogenetics Unit, Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel; Chief Physician’s Office, Clalit Health Services, Tel Aviv, Israel Technion Faculty of Medicine Carmel Medical Center Haifa Israel Carmel Medical Center Department of Community Medicine and Epidemiology, Clalit National Personalized Medicine Program, Haifa 34362, Israel. CHS National Cancer Control Center and Department of Community Medicine and Epidemiology Carmel Medical Center and Bruce Rappaport Faculty of Medicine Technion–Israel Institute of Technology Haifa Israel Authors' Affiliations: 1Environmental Health Sciences, 2Department of Otorhinolaryngology, 3Department of Internal Medicine, 4Department of Human Genetics, and 5Department of Epidemiology, School of Public Health and 6Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; 7Biostatistics and Bioinformatics Unit and 8Translational Research Laboratory, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; and 9Department of Community Medicine, Carmel Medical Center, Technion Institute of Technology, National Israeli Cancer Control Center, Haifa, Israel |
Incoming Links
Total number of triples: 333.